FindMyKOL
Clinical trialNCT04648046Active, not recruitingPhase 1/2Interventional

CAR-T Cells for HIV Infection

NCT04648046 is a phase 1/2 interventional trial sponsored by Steven Deeks. As of 21 Nov 2026, it is active and no longer recruiting. It studies Cyclophosphamide, LVgp120duoCAR-T cells, high dose and LVgp120duoCAR-T cells, low dose in HIV Infections. The registry lists an enrollment of 11 participants at 2 sites in 1 country. The registry lists a start date of 1 Mar 2021 and a primary completion date of 31 Dec 2028. One of its registered investigators has a FindMyKOL profile.

SponsorSteven Deeks →Enrollment11HIV Infections
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT04648046
FieldValue
Registry IDNCT04648046
StatusActive not recruiting
PhasePhase 1/2
Study typeInterventional trial
Lead sponsorSteven Deeks
Enrollment11
Registered sites2
Countries1
ConditionsHIV Infections
DrugsCyclophosphamide, LVgp120duoCAR-T cells, high dose and LVgp120duoCAR-T cells, low dose
Start1 Mar 2021
Primary completion31 Dec 2028
Study completion31 Dec 2029
Last update posted14 Oct 2026

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a limited-center, open-label dose escalating phase I/IIa study of autologous T cells expressing LVgp120duoCAR molecules in people with HIV infection. It will follow a 3+3 design. Dose escalation decisions will be made when a minimum of three participants have completed the safety-evaluation period (45 days) at a given dose level. Cohort 1 will undergo infusion of a single low-dose regimen of LVgp120duoCAR-T cells. Cohort 2 will undergo non-ablative conditioning with cyclophosphamide, followed by infusion of a single low-dose regimen of LVgp120duoCAR-T cells. Cohort 3 will undergo non-ablative conditioning with cyclophosphamide, followed infusion of a single high-dose regimen of LVgp120duoCAR-T cells. Following administration of the experimental therapy, HIV medications will be paused for participants in each group during an analytic treatment interruption.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

California, United States2 sites
  • University of California, Davis

    Sacramento

  • Zuckerberg San Francisco General

    San Francisco

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCalifornia: 2 sitesCA2NevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Cyclophosphamide →LVgp120duoCAR-T cells, high doseLVgp120duoCAR-T cells, low dose
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT04648046

Each answer restates registry values shown on this page.

What is NCT04648046?

NCT04648046 is a phase 1/2 interventional trial sponsored by Steven Deeks. It studies Cyclophosphamide, LVgp120duoCAR-T cells, high dose and LVgp120duoCAR-T cells, low dose in HIV Infections.

Is NCT04648046 recruiting?

As of 21 Nov 2026, it is active and no longer recruiting.

Who leads NCT04648046?

The registry names Steven Deeks, MD (principal investigator, University of California, San Francisco) as the overall official.

Where does NCT04648046 run?

The registry lists 2 sites in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT04648046 study?

The registered drug and biological interventions are Cyclophosphamide, LVgp120duoCAR-T cells, high dose and LVgp120duoCAR-T cells, low dose.

When is NCT04648046 expected to complete?

The registry lists a primary completion date of 31 Dec 2028 and a study completion date of 31 Dec 2029. The sponsor last updated the record on 14 Oct 2026.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.